Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1993-10-27
1998-12-01
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514176, 514177, 540 94, 540107, 540108, 540114, A61K 31565, A61K 3158, C07J 4100, C07J 4300
Patent
active
058439315
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to compounds of the general formula I ##STR2## in which x represents an oxygen atom or the hydroxyimino grouping >N.about.OH, C.sub.1 -Cl.sub.10 -acyloxy group, CH.sub.2 Z wherein n is 0, 1, 2, 3, 4 or 5 and Z represents a hydrogen atom, a cyano group or the radical --OR.sup.5 in which R.sup.5 .dbd.H, C.sub.1 -C.sub.10 -alkyl or C.sub.1 -C.sub.10 -acyl; the grouping --(CH.sub.2).sub.m C.tbd.C-Y wherein m is 0, 1 or 2 and Y represents a hydrogen, fluorine, chlorine, bromine or iodine atom, or a C.sub.1 -C.sub.10 -hydroxyalkyl, C.sub.1 -C.sub.10 -alkoxyalkyl or C.sub.1 -C.sub.10 -acyloxyalkyl radical; or the grouping --(CH.sub.2).sub.p --CH.dbd.CH--(CH.sub.2).sub.k CH.sub.2 R.sup.6 wherein p is 0 or 1 and k is 0, 1 or 2 and R.sup.6 represents a hydrogen atom, a hydroxy group, a C.sub.1 -C.sub.4 -alkoxy radical or a C.sub.1 -C.sub.4 -acyloxy radical, formula ##STR3## wherein x=1 or 2, R.sup.4 represents a hydrogen atom; a cyano group; a chlorine, fluorine, bromine or iodine atom; a trialkylsilyl group; a trialkylstannyl group; a straight-chain or branched, saturated or unsaturated, C.sub.1 -C.sub.8 -alkyl, -acyl or alkoxy-alkyl radical; an amino group ##STR4## in which R.sup.7 and R.sup.8, each independently of the other, represents a hydrogen atom or a C.sub.1 -C.sub.4 -alkyl group; a corresponding amine oxide ##STR5## or the grouping --OR.sup.9 or --S(O).sub.i R.sup.9 in which i=0, 1 or 2 and R.sup.9 represents a hydrogen atom, a methyl, ethyl, propyl, isopropyl, methoxyphenyl, allyl or 2-dimethyl-aminoethyl group; or R.sup.4 represents a heteroaryl radical of formula I.alpha. ##STR6## in which A represents a nitrogen, oxygen or sulphur atom, --B--D--E-- represents the sequence of elements --C--C--C--, --N--C--C-- or --C--N--C-- and R.sup.10 represents a hydrogen atom; a cyano group; a chlorine, fluorine, bromine or iodine atom; a trialkylsilyl group; a trialkylstannyl group; a straight-chain or branched, saturated or unsaturated C.sub.1 -C.sub.8 -alkyl, -acyl or alkoxyalkyl radical; an ##STR7## in which R.sup.7 and R.sup.8, each independently of the other, represents a hydrogen atom or a C.sub.1 -C.sub.4 -alkyl group; a corresponding amine oxide ##STR8## or the grouping --OR.sup.9 or --S(O).sub.i R.sup.9 in which i=0, 1 or 2 and R.sup.9 represents a hydrogen atom, a methyl, ethyl, propyl, isopropyl, methoxyphenyl, allyl or 2-dimethylaminoethyl group; ##STR9## in which A represents a nitrogen atom and --B--D--E-- represents the sequence of elements --C--C--C--, --N--C--C--, --C--N--C-- or --C--C--N-- and R.sup.10 has the meaning already given, or R.sup.4 represents a phenyl radical of formula I.gamma. ##STR10## in which R.sup.10 has the meaning already given, and G represents a hydrogen atom, a halogen atom or a C.sub.1 -C.sub.4 -alkyl radical, when M and Q are hydrogen atoms or together are an additional bond, atoms, or hydrogen atom, processes for their preparation, to pharmaceutical compositions containing those compounds, to their use for the manufacture of medicaments, and to the novel intermediates required therefor.
The invention relates especially to compounds in which X represents an oxygen atom.
The alkoxy, acyloxy, alkyl, acyl and hydroxyalkyl groups contained in R.sup.2, R.sup.3, R.sup.5 and Y in the general formula I shall each have from 1 to 10 carbon atoms, and the alkoxyalkyl or acyloxyalkyl groups in Y shall each have from 2 to 10 carbon atoms. There may be mentioned as preferred alkoxy groups methoxy, ethoxy, propoxy and isopropoxy groups, and of the acyl(oxy) groups, formyl-(oxy), acetyl(oxy) and propionyl(oxy) are of particular importance.
The alkyl groups are especially methyl, ethyl, propyl, isopropyl and tert.-butyl groups and, of the hydroxyalkyl groups, the corresponding radicals substituted at any position by a hydroxy group are preferred.
There comes into consideration for n especially 0, 1, 2 or 3; when Z .dbd.CN, a cyanomethyl group (n.dbd.0) is especially preferred. In addition to the groups already mentioned, Y may preferably also be a hydrogen
REFERENCES:
patent: 4870069 (1989-09-01), Ottow et al.
Chwalisz Krzysztof
Cleve Arwed
Elger Walter
Ottow Eckhard
Schneider Martin
Berch Mark L.
Kifle Bruck
Shering Aktiengesellschaft
LandOfFree
6,7-modified 11.beta.-aryl-4-oestrenes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6,7-modified 11.beta.-aryl-4-oestrenes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6,7-modified 11.beta.-aryl-4-oestrenes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395762